喘可治注射液联合沙美特罗替卡松治疗慢性阻塞性肺疾病急性加重期患者的疗效及对免疫功能的影响  

Analysis on effect of Chuankezhi injection combined with salmeterol fluticasone on immune function in chronic obstructive pulmonary disease with acute aggravating period

作　　者：王道峰[1] 伏俊[1] 何世贵[1] 闻寅[1] 

机构地区：[1]江苏省泰兴市人民医院呼吸内科,225400

出　　处：《疑难病杂志》2015年第9期917-920,共4页Chinese Journal of Difficult and Complicated Cases

摘　　要：目的探讨喘可治注射液联合沙美特罗替卡松治疗慢性阻塞性肺疾病急性加重期患者的疗效及对免疫功能的影响。方法 2011年6月—2014年10月收治的85例慢性阻塞性肺疾病急性加重期患者,随机分为观察组(43例)和对照组(42例),观察组使用喘可治注射液联合沙美特罗替卡松治疗,对照组使用沙美特罗替卡松治疗,比较2组患者治疗效果、肺功能变化、炎性指标(CRP、IL-8、TNF-α)和T淋巴细胞亚群变化。结果观察组总有效率97.67%,对照组总有效率88.10%,2组比较差异无统计学意义(x^2=2.97,P>0.05);治疗前2组患者第1秒用力呼气容积(FEV_1)、第1秒用力呼气容积占肺活量比重(FEV_1/FVC)、第1秒用力呼气容积占预计量比重(FEV_1%)比较差异无统计学意义(P>0.05),治疗后观察组和对照组均有显著提高(t_观=9.99、6.46、8.40,t_对=5.15、3.52、5.44,P<0.05),且观察组提高程度优于对照组(t=3.79、2.34、2.46,P<0.05);2组患者治疗前血清CRP、IL-8、TNF-α水平比较差异无统计学意义(P>0.05),治疗后均有明显降低(P<0.05,P<0.01),且观察组低于对照组(P<0.01);治疗前观察组与对照组CD_3^+、CD_4^+、CD_8^+、CD_4^+/CD_8^+水平无差异(P>0.05),治疗后均得到明显改善(P<0.05,P<0.01);治疗后观察组CD_3^+、CD_4^+、CD_4^+/CD_8^+水平高于对照组,CD_8^+水平低于对照组,差异具有统计学意义(P<0.01)。结论喘可治注射液联合沙美特罗替卡松治疗对慢性阻塞性肺疾病急性加重期患者治疗效果确切,明显改善患者肺功能,提高患者免疫功能。Objective To investigate the efficacy of Chuankezhi injection combined with salmeterol fluticasone on im-mune function in patients with chronic obstructive pulmonary disease （ COPD） .Methods From June 2011 to October 2014 , 85 cases of chronic obstructive pulmonary disease with exacerbation were randomly divided into two groups , observation group （43 patients） and control group （42 cases）, the observation group received Chuankezhi injection combined with salmeterol fluticasone propionate therapy , the control group received salmeterol fluticasone propionate therapy , therapeutic effect , lung function changes , inflammatory markers （ CRP, IL-8, TNF-α） and T lymphocyte subsets were compared between the two groups of patients.Results The total efficiency was 97.67%in the observation group, the control group’s total efficiency was 88.10%, the two groups showed no significant difference （χ2 =2.97, P 〉0.05）;before treatment, patients in the 2 groups had no statistically significant difference of following indexes：forced expiratory volume in one second （ FEV1 ） , forced expira-tory volume in 1 second proportion accounted for FVC （ FEV1/FVC） , forced expiratory volume in 1 second%predicted vol-ume proportion （FEV1%） （ P ＆gt;0.05）, after treatment, both of observation group and the control group revealed significant-ly increased of these indexes （observation group：t =9.99,6.46,8.40,control group：t =5.15, t =3.52, t =5.44, P 〈0.05）,and the degree of increase in the observation group were better than the control group （ t =3.79, t =2.34, t =2.46, P 〈0.05）;before treatment, serum CRP, IL-8, TNF-αlevel revealed no difference between the two groups （ P〉0.05）, after treatment, both of the two groups’ indexes were significantly decreased （ P 〈0.05）, and the observation group were better than the control group （ P 〈0.05）;before treatment, both groups’ CD3＋, CD4＋, CD8＋, CD4＋/CD8＋revealed no differ-ences （ P 〉0.05）;after treatment

关 键 词：喘可治 沙美特罗 慢性阻塞性肺疾病 免疫功能 

分 类 号：R563.9[医药卫生—呼吸系统]